Skip to main content
Journal cover image

Mecamylamine increases nicotine preference and attenuates nicotine discrimination.

Publication ,  Journal Article
Rose, JE; Sampson, A; Levin, ED; Henningfield, JE
Published in: Pharmacol Biochem Behav
April 1989

Eight subjects evaluated various qualities of cigarette smoke after being given a range of doses (0, 2.5, 10 and 20 mg) of the nicotinic receptor blocker mecamylamine. In one test condition, subjects were given either high or low nicotine tobacco smoke to determine the effects of mecamylamine on their subjective responses. In another test condition, subjects were allowed to adjust the nicotine dose level of the smoke to determine the effects of mecamylamine on dose preference. When the subjects evaluated puffs of smoke with high and low nicotine content, mecamylamine caused a dose-related decrease in the self-rated strength and harshness of the high nicotine dose level smoke. In contrast, there was little effect on the low dose smoke. At the highest mecamylamine dose (20 mg) there was no significant difference in the ratings of high and low nicotine cigarettes. Low doses of mecamylamine decreased the reported desire for a cigarette, and also attenuated the reduction in desire for a cigarette caused by smoking. When the subjects were allowed to select their preferred level of nicotine intake using a smoke mixing device, the 10 and 20 mg doses of mecamylamine caused a significant increase in self-administered nicotine dose level. Despite this compensatory increase in nicotine self-administration, the reduction in desire for a cigarette after smoking was still less than after placebo.

Duke Scholars

Published In

Pharmacol Biochem Behav

DOI

ISSN

0091-3057

Publication Date

April 1989

Volume

32

Issue

4

Start / End Page

933 / 938

Location

United States

Related Subject Headings

  • Smoking
  • Self Administration
  • Personal Satisfaction
  • Nicotine
  • Neurology & Neurosurgery
  • Middle Aged
  • Mecamylamine
  • Male
  • Humans
  • Drive
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rose, J. E., Sampson, A., Levin, E. D., & Henningfield, J. E. (1989). Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacol Biochem Behav, 32(4), 933–938. https://doi.org/10.1016/0091-3057(89)90061-0
Rose, J. E., A. Sampson, E. D. Levin, and J. E. Henningfield. “Mecamylamine increases nicotine preference and attenuates nicotine discrimination.Pharmacol Biochem Behav 32, no. 4 (April 1989): 933–38. https://doi.org/10.1016/0091-3057(89)90061-0.
Rose JE, Sampson A, Levin ED, Henningfield JE. Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacol Biochem Behav. 1989 Apr;32(4):933–8.
Rose, J. E., et al. “Mecamylamine increases nicotine preference and attenuates nicotine discrimination.Pharmacol Biochem Behav, vol. 32, no. 4, Apr. 1989, pp. 933–38. Pubmed, doi:10.1016/0091-3057(89)90061-0.
Rose JE, Sampson A, Levin ED, Henningfield JE. Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacol Biochem Behav. 1989 Apr;32(4):933–938.
Journal cover image

Published In

Pharmacol Biochem Behav

DOI

ISSN

0091-3057

Publication Date

April 1989

Volume

32

Issue

4

Start / End Page

933 / 938

Location

United States

Related Subject Headings

  • Smoking
  • Self Administration
  • Personal Satisfaction
  • Nicotine
  • Neurology & Neurosurgery
  • Middle Aged
  • Mecamylamine
  • Male
  • Humans
  • Drive